24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Pregnant Women Need to Guard Against CoronavirusCollege Students Feeling the Strain of Social DistancingHow One Patient's Battle With COVID-19 Changed U.S. Testing ProtocolsMission Possible: Tips for Safe Grocery Shopping During the PandemicTrials Begin for Potential COVID-19 Drug RemdesivirSchool Closures Will Force Many U.S. Health Care Workers to Stay HomeWith Coronavirus a Threat, Stop Wearing Contact LensesSome Steroid Meds May Raise Coronavirus RiskAmericans Got the Memo on Social Distancing, Poll ShowsCDC Urges All Americans to Wear Face Masks as Death Count RisesAHA News: Amid Coronavirus Crisis, Exercise Caution When Exercising OutdoorsAsthma, COPD Raise Odds for Severe COVID-19, Lung Experts WarnCoronavirus Hangs Around Even After Symptoms SubsideCan Food From an Infected Cook Give You COVID-19?Pregnant Women Need to Guard Against CoronavirusVitamin D Might Aid Seniors' Recovery From Hip Fracture: StudyWith 3D Printer, N.Y. Hospital Converts Sleep Apnea Machines Into VentilatorsAnother COVID-19 Vaccine Being Tested in Mice'Stay at Home' Orders Are Stressing U.S. Families, Survey ShowsAn Expert's Guide to Fighting Coronavirus StressHeart Patients Need to Be Wary of CoronavirusU.S. Coronavirus Cases Pass 200,000, as Jobless Claims Soar to 10 MillionIs Thyroid Hormone Dangerously Overprescribed in Older Patients?'Pink Eye' Often a Symptom of COVID-19, and Infection Via Tears PossibleMild COVID-19 Often Appears With Only Gastro Symptoms: StudyFDA Pulls Heartburn Drug Zantac From MarketCertain Health Conditions Up Risks for Severe COVID-19Parents, Arm Your Kids Against COVID-19 With Good Hand-Washing HabitsFDA Approves Malaria Drugs to Treat COVID-19, Despite Little Proof They Work'Fever Tracker' Suggests Social Distancing Is Already WorkingDon't Fall Prey to COVID-19 ScammersBeing Chained to Your Desk Might Harm Your ThyroidWhat You Should Know If Your Surgery Has Been Put on HoldAnother Coronavirus Health Threat: Too Few Asthma InhalersOdds of Hospitalization, Death With COVID-19 Rise Steadily With Age: StudyAHA News: Health Emergency? Don't Hesitate to Get HelpToo Many Patients, Too Few Ventilators: How U.S. Hospitals Cope With COVID-19AI Might Spot Which COVID-19 Patients Are at Risk of Severe DiseaseWhat Dental Offices Are Doing to Prevent Coronavirus Infection?A Parent's Guide to Fighting Coronavirus StressTrump Extends Social Distancing to April 30 as COVID-19 Cases SurgeRecovery From Mild Brain Trauma Takes Longer Than Expected: StudyStaying at Home During the Pandemic? Use Technology to Stay ConnectedAHA News: Understanding the Basics of 'Herd Immunity'Multiple Measures of Social Distancing Required to Slow Coronavirus: StudyCough, Fever, Fatigue? Head to CDC's Online Coronavirus Symptom CheckerThree Countries Have Kept Coronavirus in Check; Here's How They Did ItTrial Finds Acupuncture May Help Prevent MigrainesSevere COVID-19 Might Injure the HeartWhy Are Teens, Millennials Ignoring Coronavirus Warnings?
Questions and AnswersLinks
Related Topics

Diabetes

Don't Believe All the 'Science' on CBD Products

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Mar 16th 2020

new article illustration

MONDAY, March 16, 2020 (HealthDay News) -- Cannabidiol -- commonly known as CBD -- might not be all it is touted to be, new research suggests.

Instead, existing evidence on the potential benefits of the compound found in marijuana and hemp has often been backed by industry, scientists said.

The researchers found that of 99 human CBD studies done since 2014, about 62% had some conflict of interest -- including industry funding, or a study author employed by a company that markets CBD products.

And those studies were more likely to reach positive conclusions, versus research with no industry ties.

The findings are not surprising, experts said. It's known from drug studies that industry funding is linked to a greater likelihood of positive results.

But at a time when CBD is showing up in everything from oils and lotions to coffee and cookies -- and consumers tend to see it as "natural" -- the findings may serve as a reminder to remain savvy.

"This gives consumers an idea of where the research is coming from," said study author Joshua Wallach, an assistant professor of epidemiology at Yale School of Public Health, in New Haven, Conn.

So when you hear or read that a study supports CBD for a particular use, he said, you might want to "think critically" about the source of that research.

Wallach also suggested keeping the "bigger picture" in mind. At this point, CBD is approved by the U.S. Food and Drug Administration for only one indication: certain rare forms of epilepsy. In 2018, Epidiolex -- a purified, pharmaceutical-grade CBD -- got the nod for treating the seizure disorders Dravet syndrome and Lennox-Gastaut syndrome.

As for the array of other CBD health claims -- easing conditions like chronic pain, anxiety and insomnia -- the jury is still out. The CBD products being sold in capsules, food and cosmetics have not been evaluated by the FDA.

CBD is one of hundreds of chemicals found in marijuana. It differs from THC, the source of the famous marijuana "high." CBD is present in marijuana but is more abundant in hemp -- cannabis plants that have little THC.

The recent explosion in consumer CBD products is not the result of research evidence, but of a change in federal law. In 2018, Congress lifted a decades-old ban on growing hemp. Licensed farmers can now grow the plant, provided it contains less than 0.3% THC.

For the new study, published online March 17 in the Annals of Internal Medicine, Wallach's team found 417 CBD-related articles published in medical journals between 2014 and 2019.

Most -- 318 -- were either based on lab studies or were commentaries or reviews on existing research. The remaining 99 articles described human studies.

Of those, most focused on neurological conditions (52.5%) or mental health (17%). (Wallach and his colleagues did not break them down by specific indication.) And the majority -- nearly two-thirds -- had some kind of industry involvement, Wallach said.

Industry links, in turn, were related to the likelihood of "supportive" conclusions -- where authors either reported that CBD treatment was effective, or made recommendations on using the compound.

Overall, 74% of those publications came to supportive conclusions, versus about 65% of those without industry involvement, and 55% of articles that made no disclosures about conflicts of interest.

According to Wallach, it all suggests there "could be some spin going on," with some CBD research essentially being used as a marketing tool.

It is also possible that industry-backed research is better done and more likely to yield positive results, according to Dr. Peter Lurie, president of the nonprofit Center for Science in the Public Interest.

It's also unclear how much of the research was specifically related to Epidiolex, he noted.

That said, Lurie agreed that consumers should be aware of who is funding CBD research. "You want research to be conducted," he said. "But whether you want it to be supported by industry is another thing."

Like Wallach, Lurie pointed to the broader issue. "There are health claims about CBD that are completely unfounded," he said. "Outside of its use for epilepsy, I would see everything else as speculative."

More information

The U.S. Food and Drug Administration has more on CBD.